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Abstract
Background: Treatment and morbidity control of schistosomiasis relies on a single drug, praziquantel. Hence, there is a
pressing need to develop additional therapeutics against schistosomiasis. The antimalarial drug mefloquine shows
antischistosomal activity in animal models and clinical trials, which calls for further investigations.
Methodology: We comparatively assessed the efficacy and tolerability of the following treatments against Schistosoma
haematobium in school-aged children in Coˆte d’Ivoire: (i) praziquantel (40 mg/kg; standard treatment); (ii) mefloquine
(25 mg/kg) combined with praziquantel (40 mg/kg); and (iii) mefloquine-artesunate (36 (100 mg artesunate +250 mg
mefloquine)) combined with praziquantel (40 mg/kg) (treatments administered on subsequent days). Two urine samples
were collected before, and on days 21–22 and 78–79 after the first dosing.
Principal Findings: Sixty-one children were present on all examination time points and had complete datasets. No
difference in efficacy was observed between the three treatment groups on either follow-up. On the 21–22 day
posttreatment follow-up, based on available case analysis, cure rates of 33% (95% confidence interval (CI) 11–55%), 29%
(95% CI 8–50%), and 26% (95% CI 5–48%) were observed for praziquantel, mefloquine-artesunate-praziquantel, and
mefloquine-praziquantel, respectively. The corresponding egg reduction rates were 94% and above. On the second follow-
up, observed cure rates ranged from 19% (praziquantel) to 33% (mefloquine-artesunate-praziquantel), and egg reduction
rates were above 90%. Praziquantel monotherapy was the best tolerated treatment. In the mefloquine-artesunate-
praziquantel group, adverse events were reported by 91% of the participants, and in the mefloquine-praziquantel group,
95% experienced adverse events. With the exception of abdominal pain at moderate severity, adverse events were mild.
Conclusions/Significance: The addition of mefloquine or mefloquine-artesunate does not increase the efficacy of
praziquantel against chronic S. haematobium infection. Additional studies are necessary to elucidate the effect of the
combinations against acute schistosomiasis.
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Introduction
Schistosomiasis is a neglected tropical disease caused by a
chronic infection with blood-dwelling parasitic flatworms of the
genus Schistosoma [1]. More than 230 million people in the tropics
and subtropics are infected and the global burden of schistosomi-
asis is estimated at 3.3 million disability-adjusted life years
(DALYs) [2,3]. The main strategy to control schistosomiasis is
preventive chemotherapy that is the periodic administration of the
antischistosomal drug praziquantel to populations at-risk of
morbidity, most importantly school-aged children [4–6]. Although
no clinically relevant resistance to praziquantel has been
documented thus far, reliance on a single drug is a risky endeavor
[7,8]. Moreover, praziquantel is quite ineffective against the young
developing stages of schistosomes [9,10]. To address this inherent
shortcoming of praziquantel, treatment of acute infections will
have to be repeated or postponed until worms will have matured
[1]. It is thus essential to find additional therapeutics against
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schistosomiasis, ideally compounds that are active against all stages
of the parasite.
There is presently no other broad-spectrum antischistosomal
drug available and the drug development pipeline is empty.
Against this background and taking into consideration scarce
resources for research and development of neglected tropical
diseases, repurposing of drugs that are already approved for
human use is a promising strategy [11]. Indeed, such a strategy is
more rapid, less risky, and less costly than developing new drugs
[12,13].
Since 2008, the antimalarial drug mefloquine is undergoing
detailed in vitro, in vivo, and clinical investigation for its trematocidal
properties. For example, in the Schistosoma mansoni-mouse model,
mefloquine exhibited high worm burden reductions following
single-dose regimen against juvenile and adult schistosomes [14–
16]. Mefloquine also revealed a high activity against the other two
major human schistosome species, S. haematobium [17] and S.
japonicum [14,18]. It was therefore concluded that mefloquine has a
similarly broad spectrum of activity than praziquantel. In an
exploratory trial in Coˆte d’Ivoire, a mefloquine-artesunate
combination showed a moderate cure rate (61%) and high egg
reduction rate (96%) in school-aged children infected with S.
haematobium [19]. Recently, mefloquine, used as intermittent
preventive therapy against malaria in pregnancy (IPTp), showed
high egg reduction rates in women with a concomitant S.
haematobium infection [20]. However, combination therapy with
mefloquine and praziquantel, which showed high worm burden
reductions in laboratory animals [21], has not yet been studied in
Schistosoma-infected patients.
The aim of the current study was to assess the efficacy and
tolerability of mefloquine and mefloquine-artesunate combined
with praziquantel against S. haematobium in school-aged children.
Since prior in vivo studies revealed synergistic effects when
mefloquine and praziquantel were administered on subsequent
days, and drug interaction between mefloquine and praziquantel
have not been studied before, drug administration of the
antimalarials and praziquantel was spaced by a day. For
comparison, one group of children was treated with praziquantel
only, using the current standard dose of 40 mg/kg. Treatment
outcomes were assessed twice, on days 21–22 and 78–79 after the
first dosing to determine the effect against pre-patent and patent S.
haematobium infection.
Methods
Ethics Statement
Ethical clearance was obtained by the ethics committee in Basel
(EKBB; reference no. 70/08) and the Ministe`re de la Sante´ et de
l’Hygie`ne Publique en Coˆte d’Ivoire. Parents/guardians of
participating children signed a written informed consent for their
children, and children assented orally. Participation was voluntary
and the children were informed that they could withdraw anytime
without further obligation. The trial is registered with Current
Controlled Trials (ISRCTN00393859).
Study Site
The study was carried out in Sahoua, a village in the Taabo
district, located about 170 km north-west of Abidjan, the
economic capital of Coˆte d’Ivoire. Sahoua is situated in the V-
Baoule´, the transition zone between the rainforest in the South
and the Savannah in the North, at the north-western edge of the
Taabo health and demographic surveillance system (HDSS) [22].
The climate is tropical with the main rains occurring between
April and July and in September/October. People are primarily
engaged in subsistence farming (e.g., cassava, plantains, and yams),
whilst cacao is the predominant cash crop. The village of Sahoua
is close to the Bandama River. The inhabitants coming from
neighboring countries Mali and Burkina Faso are fishers. Women
perform household chores (e.g., washing dishes or clothes) at the
water’s edge. School-aged children are in frequent contact with the
water during recreational activities (e.g., bathing and swimming).
Study Flow
The field and laboratory work was carried out between
November 2011 and February 2012. The study aim was explained
and approved by the local health authorities, including the
director of Taabo-Cite´ hospital, the district health officer of
Tiassale´, the village chief, and the school director. Parents/
guardians of the children provided written informed consent, while
children assented orally. All school children from grade 3 (CE1) to
6 (CM2) were invited to participate in the prescreening. A total of
130 school children provided a urine sample. Urine samples were
collected between 10:00 and 14:00 hours and labeled with unique
identifiers. Samples were transferred to the laboratory of the
Taabo-Cite´ hospital for macroscopic and microscopic examina-
tion of S. haematobium. 77 children were identified as positive and
invited to participate in the study. These children were asked to
provide an additional urine sample and a stool sample the next
day. Those children who had complete parasitological datasets
were invited for a clinical examination, which included a physical
examination, weight measurement (using an electronic balance
recording to the nearest 0.1 kg), assessing temperature (using
battery-powered ear thermometers to the nearest 0.01uC), and a
finger-prick blood sample. From the blood sample, hemoglobin
concentration was determined using a portable Hemocue 301
(HemoCue AB; A¨ngelholm, Sweden). Additionally, thick and thin
blood films were prepared on microscope slides, labeled with
unique identification numbers, and air-dried.
Author Summary
The antimalarial drug mefloquine shows activity against
blood flukes that cause the disease schistosomiasis. In
animal studies it has been found that a mefloquine-
praziquantel combination kills blood flukes more effec-
tively than praziquantel alone. Combining praziquantel
with another drug might therefore increase efficacy,
broaden the spectrum of activity, and delay the develop-
ment of drug resistance. We designed a study in Ivorian
school children to assess the efficacy and tolerability of
mefloquine and mefloquine-artesunate combined with
praziquantel against the blood fluke Schistosoma haema-
tobium. The administration of the antimalarials and
praziquantel was spaced by a day. Treatment outcomes
were assessed twice, on days 21–22 and 78–79 after the
first dosing to determine the effect against adult and
juvenile S. haematobium, respectively. At both follow-ups,
high reduction in the intensity of infection (egg reduction
rates of 94–96%), but low cure rates (26–33%) were
observed in the three treatment groups. Adverse events
were common, particularly in children treated with
mefloquine-praziquantel and mefloquine-artesunate-praz-
iquantel. Our study suggests that the addition of meflo-
quine and mefloquine-artesunate to praziquantel has no
benefit in the treatment of chronic S. haematobium
infection. However, further investigations are warranted
to evaluate the effect of combination therapy on juvenile
flukes and longer-term morbidity profiles.
Mefloquine plus Praziquantel against Schistosoma haematobium
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Children were excluded if any of the following criteria were met:
(i) fever (temperature $37.5uC); (ii) pregnancy first trimester
assessed verbally; (iii) presence of any abnormal medical condition,
judged by the study physician; (iv) history of acute or severe
chronic disease; (v) psychiatric disorders such as epilepsy; (vi)
recent use of anthelmintic or antimalarial drugs (within the past
month); and (vii) weight below 20 kg. S. haematobium-infected
children who were excluded from the study were offered
praziquantel (40 mg/kg) free of charge.
Mefloquine (250 mg lactabs), and mefloquine-artesunate blisters
containing 36100 mg artesunate and 36250 mg mefloquine were
purchased from Viktoria Apotheke (Zurich, Switzerland). Prazi-
quantel (600 mg tablets) was purchased from Inresa (Bartenheim,
France). Children included in the study received one of three
treatments under direct medical observation, following a comput-
er-generated randomization code: (i) mefloquine 25 mg/kg single
dose (body weight ,30 kg) or a split dose spaced by 6 hours (body
weight $30 kg) plus a single dose of praziquantel (40 mg/kg) on
the next day; (ii) mefloquine-artesunate (16100 mg artesunate and
16250 mg mefloquine) once daily for 3 consecutive days plus a
single dose of praziquantel (40 mg/kg) on treatment day 4; and (iii)
praziquantel, standard single dose (40 mg/kg). Mefloquine and
praziquantel were administered to the nearest half tablet according
to the calculated dose per kg of body weight. All participating
children received a snack shortly after drug administration.
Children were kept for observation and interviewed for the
presence of acute adverse events 3 hours posttreatment. In
addition, adverse events were assessed 24 hours after each
treatment dose (prior to the next dose for the mefloquine-
artesunate-praziquantel and mefloquine-praziquantel treatment
groups). Adverse events were graded (i.e., mild, moderate, severe,
and life-threatening), and symptomatic relief provided if necessary.
Laboratory Procedures
Urine samples were examined visually for macroscopic blood
and then analyzed for microhematuria using reagent strips
(Hemastix, Siemens Healthcare; Zurich, Switzerland). For detec-
tion of S. haematobium eggs, urine samples were subjected to a
filtration method [19]. In brief, samples were carefully homoge-
nized and 10 ml of urine pressed through a 13-mm diameter filter
with 25 mm pores (Sefar AG; Heiden, Switzerland). The filters
were placed on microscope slides, a drop of Lugol’s solution added
before examination under a microscope at a magnification of
6100 by two experienced technicians. Slides were re-examined by
Figure 1. Consort flowchart. Study enrollment, allocation, follow-up, and analysis.
doi:10.1371/journal.pntd.0002975.g001
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a senior technician in case of differing results among the two
technicians.
Stool specimens were subjected to duplicate Kato-Katz thick
smears, using standard 41.7 mg templates [23] and examined
under a microscope. The number of S. mansoni, Ascaris lumbricoides,
Trichuris trichiura, hookworm, and other helminth eggs were
counted and recorded for each species separately. Additionally,
approximately 2 g of stool was preserved in sodium acetate-acetic
acid-formalin (SAF), and processed with an ether-concentration
method [24]. Samples were examined microscopically at a
magnification of 6100 for helminths, and at a magnification of
6400 for intestinal protozoa (e.g., Blastocystis hominis, Chilomastix
mesnili, Endolimax nana, Entamoeba coli, Entamoeba hartmanni, Entamoeba
histolytica/E. dispar, Giardia intestinalis, and Jodamoeba bu¨tschlii).
Thick and thin blood films were stained with Giemsa, and
prepared and read as described elsewhere [19]. Parasite counts
were documented as the number of Plasmodium per ml of blood,
assuming a standard count of 8,000 white blood cells per ml of
blood.
Sample Size, Statistics, and Outcome Measures
By definition, pilot studies are conducted to serve as a starting
point for further studies and are primarily intended to yield
Table 1. Demographic and laboratory baseline characteristics of S. haematobium-infected children treated with mefloquine-
artesunate plus praziquantel, mefloquine plus praziquantel, and praziquantel.
Parameter Treatment group
Artesunate-mefloquine
plus praziquantel (n = 21)
Mefloquine plus
praziquantel (n = 19)
Praziquantel
(n = 21)
Males/females (no.) 15/6 16/3 16/5
Mean (6SD) age, years 10.4 (2.8) 10.7 (2.7) 10.9 (2.4)
Mean (6SD) weight, kg 29.1 (8.1) 29.1 (6.0) 28.0 (5.5)
Mean (6SD) height, cm 139.5 (11.8) 139.5 (10.6) 138.8 (9.9)
Mean (6SD) hemoglobin (g/dl) 11.6 (1.0) 12.0 (0.7) 12.0 (1.0)
S. haematobium infection
GM eggs/10 ml urine 61.8 45.2 45.9
AM eggs/10 ml urine 177.7 140.7 89.1
Range 1–1,198 1–1,219 1–792
Number (%) of light infection** 8 (38) 8 (42) 9 (43)
Number (%) of heavy infection 13 (62) 11 (58) 12 (57)
Urinary analysis, number (%) of children with
Microhematuria (by reagent strip)
Negative 2 (10) 4 (21) 3 (14)
Trace positive 3 (14) 2 (11) 6 (29)
Positive 16 (76) 13 (68) 12 (57)
Macrohematuria (by visual inspection)
Negative 1 (5) 4 (21) 6 (29)
Trace positive 4 (19) 5 (26) 8 (38)
Positive 16 (76) 10 (53) 7 (33)
Malariometric indices
Number (%) of children with Plasmodium 21 (100) 18 (100)* 17 (81)
Parasitemia (mean density/ml of blood) 4816 1967 3249
Number (%) of children infected with soil-transmitted
helminths
2 (10) 1 (5) 0 (0)
Number (%) of children infected with intestinal protozoa
Endolimax nana 6 (29) 10 (53) 6 (29)
Entamoeba coli 12 (57) 7 (37) 8 (38)
Giardia intestinalis 4 (19) 6 (32) 3 (14)
Chilomastrix mesnili 2 (10) 2 (11) 0
Blastocystis hominis 3 (14) 3 (16) 0
Entamoeba histolytica/E. dispar 4 (19) 2 (11) 2 (10)
Jodamoeba bu¨tschlii 0 4 (21) 0
* 18 malaria slides.
** ,50 eggs/10 ml of urine.
doi:10.1371/journal.pntd.0002975.t001
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information about the feasibility and implementation possibilities
of novel treatments. Thus, the choice of an adequate sample size
for a pilot study is mainly based on practical considerations of the
pilot trial rather than on statistical sample size calculations [25].
Allowing for up to 50% drop-outs, we aimed for 23–25 children
per treatment arm. Data were double entered into Excel and
Access (Microsoft 2010), cross-checked, and analyzed using Stata
version 10.1 (StataCorp.; College Station, United States of
America) and Statsdirect version 2.7.9 (Statsdirect, Chesire,
United Kingdom).
All children with primary endpoint data were included in the
analysis (available case analysis). S. haematobium egg counts from the
two urine samples were averaged for each child (arithmetic mean
(AM)) and the AM and geometric mean (GM) egg count for each
treatment group calculated. Cure rate (percentage of children
excreting no S. haematobium eggs at the posttreatment follow-ups
(i.e., 21–22 and 78–79 days after drug administration) among
parasitological-confirmed children at baseline) and egg reduction
rate (reduction of AM and GM egg count among S. haematobium-
positive children posttreatment compared to the respective AM
or GM pretreatment) were calculated. Bootstrap resampling
method with 10,000 replicates was used to calculate 95%
confidence intervals (CIs) for egg reduction rates of GM [26].
Differences in egg reduction rates were determined under the
assumption that non-overlapping CIs indicate statistical signifi-
cance. To test whether there was an association between cure
rates and dose, the actual doses administered were determined
and analyzed using logistic regression. To compare baseline and
follow-up parameters, Mann-Whitney U test and Wilcoxon
matched pairs test were used, as appropriate. Pearson’s x2 was
used to compare the proportion of reported adverse events
between treatment arms.
Table 2. Effect of artesunate-mefloquine plus praziquantel, mefloquine plus praziquantel, and praziquantel on S. haematobium
and concomitant co-infections at the first treatment follow-up.
Treatment
Parameter
Artesunate-mefloquine
plus praziquantel (n = 21)
Mefloquine plus
praziquantel (n =19)*
Praziquantel
(n = 21)
Mean (6SD) hemoglobin (g/dl) 12.7 (1.2) 12.6 (1.0) 12.4 (1.2)
Schistosoma haematobium infection
Cure rate (%) (95% CI) 29 (8 to 50) 26 (5 to 48) 33 (11 to 55)
Number (%) of children cured with light infections 3 (38) 4 (50) 6 (67)
Number (%) of children cured with heavy infections 3 (23) 1 (9) 1 (8)
Geometric mean (eggs/10 ml of urine) 2.3 2.4 2.7
Egg reduction rate, % (95% CI) 96 (93 to 99) 95 (91 to 98) 94 (86 to 97)
Arithmetic mean (eggs/10 ml of urine (range)) 6.4 (0–126) 5.5 (0–54) 9.0 (0–144)
Egg reduction rate, % 96 96 90
Urinary analysis, number (%) of children with
Microhematuria (by reagent strip)
Negative 15 (71) 13 (68) 15 (71)
Trace positive 5 (24) 6 (32) 5 (24)
Positive 1 (5) 0 (0) 1 (5)
Macrohematuria (by visual inspection)
Negative 13 (61.9) 10 (52.6) 15 (71.4)
Trace positive 4 (19) 4 (21) 3 (14)
Positive 4 (19) 5 (26) 3 (14)
Malariometric indices
Number (%) of children with Plasmodium 0 (0) 1 (5) 18 (86)
Parasitemia (mean density/ml of blood) 0 (0) 80 711
Co-infections (number (%) of infected children)
Hookworm 3 (14) 2 (11) 11 (52)
Intestinal protozoa
Endolimax nana 5 (24) 3 (17) 10 (48)
Entamoeba coli 12 (57) 10 (56) 8 (38)
Giardia intestinalis 5 (24) 2 (11) 0 (0)
Entamoeba histolytica/E. dispar 6 (29) 5 (28) 1 (5)
Blastocystis hominis 1 (5) 1 (6) 1 (5)
Chilomastrix mesnili 5 (24) 0 (0) 2 (10)
Jodamoeba bu¨tschlii 4 (19) 3 (17) 2 (10)
*18 SAF samples available.
doi:10.1371/journal.pntd.0002975.t002
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Results
Adherence, Participants, and Baseline Parameters
Overall, 71 S. haematobium-infected children were randomized to
the three treatment arms (Figure 1). Ten children were lost at the
first or second follow-up, mainly because of travels at the time of
the surveys. Demographic and clinical baseline characteristics of
the 61 children included in the available case analysis are
summarized in Table 1. Treatment groups were well balanced
in terms of age (mean age: 10.4–10.9 years), weight (mean weight:
28.0–29.1 kg), and height (mean height: 138.8–139.9 cm). How-
ever, more boys (n = 47) than girls (n = 14) participated in the trial.
Hemoglobin values were in the normal range.
Most of the included children suffered from heavy S. haematobium
infection, as defined by $50 S. haematobium eggs per 10 ml of urine
(n = 36, 59%). No difference was observed in infection intensity
between the three treatment groups; the GM of S. haematobium eggs
per 10 ml of urine ranged from 45.2 to 61.8. Macroscopic
examination of urine revealed visible blood in 33 samples (46%).
Indirect screening approaches based on reagent strips to detect
microhematuria and proteinuria, revealed prevalences of 82% and
85%, respectively. Most children were coinfected with Plasmodium
falciparum. No infection with S. mansoni was diagnosed. Coinfections
with hookworm were observed in three children. Intestinal
protozoa infections were common; Endolimax nana and Entamoeba
coli were the predominant species in all treatment groups.
Efficacy against S. haematobium and Concomitant
Parasitic Infections
Our results showed no difference in cure rates against S.
haematobium among the three treatment arms, at neither treatment
follow-up. At the first follow-up 21–22 days posttreatment, we
observed low cure rates; namely, 26% (95% CI 5–48%) for
Table 3. Effect of artesunate-mefloquine plus praziquantel, mefloquine plus praziquantel, and praziquantel on S. haematobium
and concomitant co-infections at the second treatment follow-up.
Parameter Treatment
Artesunate-mefloquine
plus praziquantel (n = 21)
Mefloquine plus
praziquantel (n = 19)
Praziquantel
(n = 21)
Mean (6SD) hemoglobin (g/dl) 12.9 (0.9) 12.3 (1.1) 12.0 (1.3)
Schistosoma haematobium
Cure rate (%) (95% CI) 33 (11 to 55) 21 (1 to 41) 19 (1 to 37)
Number (%) of children cured with light infections 4 (50) 2 (25) 3 (33)
Number (%) of children cured with heavy infections 2 (15) 2 (18) 1 (8)
Geometric mean (eggs/10 ml of urine) 3.7 2.7 3.5
Egg reduction rate, % (95% CI) 94 (81 to 99) 94 (86 to 98) 92 (83 to 96)
Arithmetic mean (eggs/10 ml of urine (range)) 11.2 (0–56) 4.7 (0–22) 10.9 (0–178)
Egg reduction rate, % 94 97 88
Urinary analysis, no (%) of children with
Microhematuria (by reagent strip)
Negative 13 (62) 9 (47) 11 (52)
Trace positive 4 (19) 9 (47) 9 (43)
Positive 4 (19) 1 (5) 1 (5)
Macrohematuria (by visual inspection)
Negative 12 (57) 10 (53) 14 (67)
Trace positive 7 (33) 9 (47) 6 (19)
Positive 2 (10) 0 (0) 1 (5)
Malariometric indices
Number (%) of children with Plasmodium 4 (19) 7 (37) 13 (62)
Parasitemia (mean density/ml of blood) 1,620 1,949 2,028
Co-infections (number (%) of infected children)
Hookworm 4 (19) 3 (16) 10 (48)
Intestinal protozoa
Endolimax nana 9 (43) 8 (42) 7 (33)
Entamoeba coli 12 (57) 15 (79) 10 (48)
Giardia intestinalis 4 (19) 5 (26) 3 (14)
Entamoeba histolytica/E. dispar 1 (5) 4 (21) 2 (10)
Blastocystis hominis 0 (0) 1 (5) 3 (14)
Chilomastrix mesnili 0 (0) 2 (11) 1 (5)
Jodamoeba bu¨tschlii 1 (5) 1 (5) 4 (19)
doi:10.1371/journal.pntd.0002975.t003
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mefloquine plus praziquantel, 29% (95% CI 8–50%) for meflo-
quine-artesunate plus praziquantel, and 33% (95% CI 11–55%)
for praziquantel monotherapy (Table 2). Cure rates were higher
among children with light-intensity S. haematobium infections (38–
67%). Cure rates determined with indirect screening approaches
by visual inspection of urine for macrohematuria and reagent strip
testing for microhematuria were as high as 71%.
No significant association between cure rates and exact dose was
observed. In the praziquantel treatment arm, the exact dose of
praziquantel administered ranged from 33 to 45 mg/kg; in the
mefloquine-praziquantel treatment arm, the exact dose of
mefloquine ranged from 22 to 25 mg/kg and that of praziquantel
from 33 to 45 mg/kg; in the mefloquine-artesunate-praziquantel
treatment arm, the exact dose of mefloquine ranged from 13 to
36 mg/kg, that of artesunate from 5.4 to 14.2 mg/kg, and the
administered dose of praziquantel was 33–43 mg/kg.
High egg reduction rates (94–96% based on the GM eggs per
1 g of stool (EPG)) were observed for the three treatments against
S. haematobium at the first follow-up. Additionally, all children
treated with mefloquine-artesunate plus praziquantel were cured
from Plasmodium infections. Seventeen out of 18 children treated
with mefloquine plus praziquantel had a negative laboratory
diagnosis of Plasmodium. The two groups treated with antimalarials
had significantly higher hemoglobin values (p,0.05; mean
increase of 0.57 g/dl hemoglobin in mefloquine-praziquantel
and 1.15 g/dl in mefloquine-artesunate plus praziquantel treated
children) in contrast to children treated with praziquantel alone
(mean increase of hemoglobin 0.36 g/dl). As expected, no effect
on concomitant Plasmodium infection was observed in children who
were treated with praziquantel singly. The prevalence of intestinal
protozoa infection was similar at baseline and the first treatment
follow-up.
At the second follow-up 78–79 days posttreatment, cure rates
ranged from 19% (95% CI 1–37%) (praziquantel) to 33% (95% CI
11–55%) (mefloquine-artesunate plus praziquantel) (Table 3). No
difference was observed between the three treatment arms and
cure rates. Additionally, no difference was observed between cure
rates at the first and second follow-up. Egg reduction rates were
high (92–94% based on the GM). Visual inspection and
reagent strip analysis resulted in cure rates of 53–67% and 47–
62%, respectively. Eleven children in the antimalarial treat-
ment groups had re-acquired a malaria infection. Hemoglobin
levels in children treated with mefloquine-artesunate plus
praziquantel remained significantly higher compared to base-
line values (12.9 versus 11.6 g/dl; p,0.001). In addition,
infection with E. coli were most commonly observed (37
children), followed by E. nana and hookworm infections (24 and
17 children, respectively).
Adverse Events
During the clinical examination at baseline 20 of the 61
participating children reported symptoms, mainly headache and
abdominal pain. The number of children experiencing adverse
events, stratified by treatment arm at each of the two treatment
follow-ups, is summarized in Table 4. Table 5 presents the number
of specific mild and moderate adverse events, observed in each
treatment arm assessed at different examination time points. We
did not observe any life-threatening adverse events following
treatment and, with the exception of abdominal pain at moderate
severity (12 children), adverse events were mild. Praziquantel and
mefloquine-artesunate were significantly better tolerated than
mefloquine (p,0.05), as assessed 24 hours posttreatment. Nearly
all children treated with mefloquine-artesunate plus praziquantel
(91%) and mefloquine plus praziquantel (95%) experienced
adverse events over the four respectively two treatment days.
More than half of the children (56%) stated adverse events
following a single dose of praziquantel. Abdominal pain (mild and
moderate episodes) was the most commonly observed adverse
event in all treatment groups. Children treated with mefloquine-
artesunate plus praziquantel and mefloquine plus praziquantel
reported significantly more mild abdominal pain than children
treated with praziquantel (p,0.05). Vomiting was also commonly
reported by children treated with mefloquine-artesunate plus
praziquantel (p,0.05) and mefloquine plus praziquantel. Other
common adverse events in all treatment groups included vertigo,
headache, and diarrhea.
Table 4. Number of children with adverse events among the three treatment arms, as assessed at different time points
posttreatment.
Number (%) of patients with adverse events
Time point
Artesunate-mefloquine
plus praziquantel
Mefloquine plus
praziquantel Praziquantela
Related symptoms before treatment 9 (43) 3 (16) 8 (38)
3 hours after first treatment 3 (14) 11 (58) 7 (44)
24 hours after first treatment 3 (14) 12 (63)* 2 (13)
3 hours after second treatment 12 (57) 9 (47) NA
24 hours after second treatment 6 (29) 1 (5) NA
3 hours after third treatment 11 (52) NA NA
24 hours after third treatment 8 (38) NA NA
3 hours after fourth treatment 13 (62) NA NA
24 hours after fourth treatment 2 (10) NA NA
Overall number of patients experiencing
adverse events at any time point
19 (91) 18 (95) 9 (56)
NA: not applicable.
a: 16 patients participated at adverse events examinations.
* significantly different from praziquantel (p,0.05) using Pearson’s x2 test.
doi:10.1371/journal.pntd.0002975.t004
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Discussion
Reliance on a single drug for individual treatment and
community-based morbidity control of schistosomiasis – one of
the most important parasitic diseases in sub-Saharan Africa –
bears the risk of parasites developing resistance. No alternative
antischistosomal drugs are in the development pipeline. Oxamni-
quine and metrifonate – two drugs that have been widely used
against S. mansoni and S. haematobium, respectively – are (with the
exception of oxamniquine in Brazil) no longer commercially
available [27–29]. A promising approach for identifying new drugs
against schistosomiasis is to repurpose existing drugs that are
already on the market for the treatment of other diseases. This
strategy is popular in many medical fields, including tuberculosis
[30], cancer [31], and malaria [32]. In fact, a recent analysis of the
research and development landscape of drugs and vaccines for
neglected diseases from 2000 to 2011 showed that most new drugs
in this therapeutic area are repurposed versions of existing
products [11].
In the present exploratory trial, we assessed whether
antimalarials (mefloquine and mefloquine-artesunate) plus
praziquantel have a higher efficacy than standard single-dose
praziquantel. Mefloquine and mefloquine-artesunate combina-
tion were selected as combination partner for praziquantel since
laboratory studies have shown synergistic effect for mefloquine-
praziquantel combinations in vitro and in vivo [21]. Furthermore,
stage-specific susceptibility studies have shown that, in contrast
to the biphasic activity of praziquantel, juvenile worms are
particularly vulnerable to mefloquine and the artemisinins
[14,33]. Hence, we hypothesized that a mefloquine-praziquan-
tel combination has an increased spectrum of activity compared
to praziquantel alone. Note that drugs were administered on
consecutive days as drug interactions have not been studied to
date and the treatment schedule administering the antimalarials
prior to praziquantel had achieved the highest activity in vivo
[21].
At the first posttreatment follow-up 21–22 days after drug
administration, a marked reduction in the intensity of infection
with high egg reduction rates (94–96%) but low cure rates (26–
33%) were observed in the three treatment groups. We were
surprised about the low cure rates achieved by praziquantel,
although previous studies also reported low cure rates when
administering praziquantel against S. haematobium (e.g., 40% in
Cameroon [34] and 37% in Mali [35]). As described before [6,34],
these low cure rates most likely reflect that children treated with
praziquantel had high infection intensities prior to drug admin-
istration. However, most prior studies have reported higher cure
rates. For example, Stothard and colleagues recently reviewed the
literature and meta-analyzed the data, which revealed an overall
cure rate of 70% in response to a single dose of praziquantel
against S. haematobium [6]. Unexpectedly, the co-administration of
either mefloquine or mefloquine-artesunate with praziquantel
showed similarly low cure rates than the paziquantel single
treatment group. Our findings therefore contrast with previous
studies. In Nigeria, a combination of praziquantel and artesunate
(using a similar treatment schedule than in the current investiga-
tion) achieved higher cure rates and egg reduction rates compared
to single praziquantel or single artesunate [36]. In addition, a
previous study conducted in a nearby village, revealed a cure rate
of 61% in S. haematobium-infected children treated with a
mefloquine-artesunate combination [19]. Hence, since mefloquine
and artesunate exhibit antischistosomal properties [19], we
expected to observe higher cure rates combining these antimalar-
ials with praziquantel compared to praziquantel singly. A
limitation of our study is that the viability of excreted eggs [37]
was not determined, and hence counts of dead eggs might have
been included in the analysis, and hence our reported cure rates
might underestimate the true situation.
At the second follow-up examination 78–79 days posttreatment,
cure and egg reduction rates were comparably low as in the first
follow-up. A slight (not significant) decrease in the estimated cure
rate of praziquantel was noted (from 33% to 19%). Given the
small sample size and low cure rates observed already at the first
follow-up, a conclusion whether the addition of mefloquine and/
or artesunate would expand the activity profile of praziquantel
targeting juvenile schistosomes cannot be drawn.
As expected, praziquantel was the best tolerated treatment,
perhaps explained by only one type of drug administered.
Mefloquine-praziquantel and mefloquine-artesunate-praziquantel
on the other hand were administered over 2 and 4 days,
respectively. The adverse event rate calculated as the number of
adverse events per group, divided by the person-time at risk in
each group was similar among the treatment groups (data not
shown). Whether adverse events following praziquantel adminis-
tration in the mefloquine-artesunate-praziquantel and mefloquine-
praziquantel treated children are due to praziquantel or due to the
long systemic exposure of the antimalarials is not known. Similar
to our previous study [19], most children treated with mefloquine
and mefloquine-artesunate reported mild or moderate adverse
events, mainly gastrointestinal complaints, including abdominal
pain, nausea, and vomiting.
In conclusion, our results suggest that a drug combination
containing mefloquine-artesunate or mefloquine has no benefit
over standard praziquantel against chronic S. haematobium infection
regarding efficacy (cure and egg reduction rate) and safety
(frequency and severity of adverse events). Further studies are
required to elucidate the effect of these combinations on acute
schistosomiasis. There is a pressing need to develop additional
antischistosomal drugs, as long as praziquantel remains efficacious
against different Schistosoma species parasitizing man.
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